News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Wall Street Zen has downgraded Precision BioSciences (NASDAQ:DTIL) to a "Sell" rating from "Hold," despite a broader analyst consensus of "Moderate Buy" with a $32.25 price target. The company recently reported a quarterly loss of $1.26 per share, missing analyst expectations. Institutional investors hold …
PRECISION BIOSCIENCES INC (DTIL) reported its Q2 2026 financial results, showing zero revenue and a net loss of $32.65M, which is a wider loss compared to the previous year. Despite the financial losses, the company highlighted significant progress in its clinical programs, including advancements …
This article analyzes Precision Biosciences Inc. (DTIL) using AI models to provide trading strategies and risk zones. It highlights a positive near-term sentiment within a long-term strength context, despite a mid-term weak bias, and identifies a significant risk-reward setup. The analysis offers specific entry, …
Precision BioSciences announced its second-quarter 2026 financial results, highlighting a strong financial position with cash and equivalents expected to fund operations into the second quarter of 2028. The company reported a net loss and significant research and development expenses, while also providing updates on …
This page provides comprehensive financial data for Precision BioSciences, Inc. (DTIL), including its stock price, historical performance, key financial metrics, and analyst ratings. It details the company's focus on gene editing therapies and its development pipeline, such as treatments for chronic hepatitis B and …
This article reports that Precision BioSciences Inc. filed a Form 8K on August 6th, as published by Investing.com. The content of the filing itself is not detailed, but the article reiterates the news across several sections. It primarily serves as an announcement of the …
Analysts have significantly downgraded their revenue forecasts for Precision BioSciences, Inc. (NASDAQ:DTIL) for 2026, now expecting US$13m, a 72% decline, and increased their loss per share estimates to US$2.96. This revised outlook reflects a more conservative view, predicting the company's revenue will decline at …
Sharemaestro market context Price below Trend Line 52 weeks -32.1% · Next-week setup negative 39.4%Precision BioSciences CFO Naresh Tanna has filed an initial SEC Form 3, disclosing direct ownership of 25,575 common shares. The filing also detailed restricted stock units (RSUs) totaling 226,006. This information was generated by Public Technologies using AI from an SEC filing.
Naresh Haresh Tanna, the Chief Financial Officer of Precision Biosciences Inc (DTIL), has reported his direct ownership of 25,575 shares of common stock. Additionally, he received several Restricted Stock Unit (RSU) grants totaling 16,683, 33,317, 45,000, and 179,340 units, which will vest in three …
Mei Zhang Lu, Chief Accounting Officer of Precision Biosciences Inc. (DTIL), has reported her direct ownership of 5,115 shares of common stock. Additionally, her holdings include fully vested employee stock options for 2,340 shares with various exercise prices and expiration dates, and restricted stock …
H.C. Wainwright has reiterated a Buy rating and a $60.00 price target for Precision BioSciences Inc. (NASDAQ: DTIL) following a management meeting. The firm highlighted the company's strong cash position relative to debt and upcoming catalysts in late 2026 for its clinical programs targeting …
Precision BioSciences' Chief Scientific Officer, Cassandra Louise Gorsuch, has disclosed her equity holdings in the company. The report details her direct ownership of 16,028 shares of Common Stock, fully vested employee stock options covering 820 shares, and Restricted Stock Units (RSUs) for a total …
Precision BioSciences Inc (DTIL) currently holds a valuation score of 7.84, placing it 140th out of 385 in the Biotechnology & Medical Research industry. The company's current P/E ratio is -3.33, which is significantly below its recent high and above its recent low. Key …
This article provides a comprehensive stock analysis of Precision BioSciences Inc (DTIL), highlighting its strong fundamentals, high growth potential, and "Strong Buy" analyst rating. Despite recent weak stock market performance, the company is developing gene editing therapies using its proprietary ARCUS platform and is …
Precision BioSciences, Inc. announced that it will release its second-quarter 2026 financial results and provide a business update on Thursday, August 6, 2026. The company is a clinical-stage gene editing firm utilizing its ARCUS® platform to develop in vivo gene editing therapies for various …
Precision BioSciences Inc (DTIL) has an institutional shareholding score of 5.00, placing it 132nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 60.88%, a significant increase of 64.56% quarter-over-quarter. James Simons is the largest institutional shareholder, though his holding percentage …
This article provides a risk assessment for Precision BioSciences Inc (DTIL), highlighting its current risk score of 2.44 within the Biotechnology & Medical Research industry and a beta of 1.31 against the S&P 500. It details various volatility metrics, including maximum drawdown, daily returns, …
This article provides a technical analysis of Precision BioSciences Inc (DTIL), focusing on its stock score, support and resistance levels, and various technical indicators and moving averages. The stock is currently trading between a resistance level of 8.85 and a support level of 5.93, …
Precision BioSciences (NASDAQ: DTIL) has announced a significant restructuring of its senior leadership team, effective August 1, 2026. Alex Kelly has been promoted to Chief Operating Officer, while Naresh Tanna is the new Chief Financial Officer, and Mei Burris will assume responsibilities as Chief …
The article analyzes the financial health of Precision BioSciences Inc (DTIL), highlighting its strong financial score of 8.85, ranking 23rd in its industry. The company shows robust financial status and high operating efficiency, with a significant year-over-year revenue increase of 37272.41% and a net …
Empery Asset Management, LP and Ryan M. Lane have reported a beneficial ownership of 4.99% in Precision BioSciences, Inc., totaling 1,314,393 shares, which includes 538,300 shares exercisable from warrants. A 4.99% beneficial ownership blocker prevents further warrant exercise if it would push their stake …
Precision BioSciences (NASDAQ:DTIL) has announced key changes to its senior leadership team, effective August 1st. Alex Kelly will transition from CFO to the newly created role of Chief Operating Officer, while Naresh Tanna will become the new Chief Financial Officer. These changes are intended …
Precision BioSciences has announced significant executive leadership changes, effective August 1, 2026. Alex Kelly, previously CFO, has been promoted to Chief Operating Officer, and Naresh Tanna will step into the role of Chief Financial Officer. Additional executive changes include Mei Burris as Principal Accounting …
Search by ticker symbol or company name and select a result to open its chart.